poisar

Stocks · News reference

Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results and Business Updates

Tactile Medical reported Q3 2026 revenue of $91.9 million, raised its full-year Adjusted EBITDA outlook, and announced several operational and regulatory milestones.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TCMD
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. The Motley Fool Team

    Tactile Systems: 3 Key Takeaways for Long-Term Investors

    Tactile Systems raised full-year adjusted EBITDA guidance to $50-52 million, driven by 13% year-over-year growth in lymphedema product revenue to $81.8 million and operational improvements that reduced medical record review times by 50%. The company is absorbing temporary inventory delays in its airway clearance business through margin expansion and controlled spending, while positioning itself for sustained growth through expanded sales teams and AI-enabled order management systems.

    TCMD
  4. David Kretzmann

    Tactile Medical's Spending Outpaces Sales: Rapid Earnings Reaction

    Tactile Systems Technology reported Q3 revenue growth of 7% to $91.9 million, but net income declined to $7.2 million from $8.2 million as operating expenses grew at the same pace as sales. While the core lymphedema business grew 13%, the smaller airway clearance line contracted 25% due to inventory adjustments from a product launch. The company maintained its 2026 revenue guidance but slightly raised profit forecasts, though Q4 adjusted EBITDA is expected to be 2-10% below last year.

    TCMD